|
Thursday, February 1, 2024 |
|
Eisai Commences Fully-Fledged Business Activities at Pharma Sales Subsidiary in South Africa |
Eisai Co., Ltd. announced today that fully-fledged operations have begun at Eisai Pharmaceuticals Africa (Pty) Ltd, a pharmaceutical sales subsidiary recently established in Johannesburg, South Africa, and direct sales operations and business activities have commenced in Africa. more info >> |
|
Friday, January 26, 2024 |
|
Eisai Submits New Drug Application for Mecobalamin Ultrahigh-Dose Formulation in Japan for the Indication of Amyotrophic Lateral Sclerosis |
Eisai Co., Ltd. announced today that it has submitted a New Drug Application (NDA) for ultrahigh-dose mecobalamin (development code: E0302) for the indication of amyotrophic lateral sclerosis (ALS) to the Pharmaceuticals and Medical Devices Agency (PDMA) in Japan. more info >> |
|
Thursday, January 18, 2024 |
|
Eisai: Antiepileptic Drug Fycompa Injection Formulation Approved in Japan |
Eisai Co., Ltd. announced today that it has obtained marketing authorization approval from the Japanese Ministry of Health, Labour and Welfare for the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa (perampanel) in Japan as an alternative therapy when oral administration is temporarily not possible. more info >> |
|
Wednesday, January 17, 2024 |
|
Eisai Listed as a Global 100 Most Sustainable Corporation for the Eighth Time |
Eisai Co., Ltd. announced today that it has been listed in the 2024 Global 100 Most Sustainable Corporations in the World (Global 100), a global ranking by Canada-based media and investment advisory company, Corporate Knights, Inc. more info >> |
|
Tuesday, January 16, 2024 |
|
Eisai Furthers Oncology Research Across Multiple Cancers at ASCO GI and ASCO GU 2024 |
Eisai Co., Ltd. announced today the presentation of oncology research at two upcoming medical meetings taking place in-person in San Francisco, California and virtually. more info >> |
|
エーザイ、ASCO GI および ASCO GU において複数のがんに対する最新の開発研究に関する演題を発表 |
more info >> |
|
Thursday, January 11, 2024 |
|
Eisai: The Scientific Advisory Group (SAG) to Convene to Discuss the Marketing Authorization Application for lecanemab in the EU |
Eisai Co., Ltd. announced today that the Scientific Advisory Group (SAG) will convene to discuss the marketing authorization application (MAA) of lecanemab (generic name, brand name: LEQEMBI), which is currently under review by the European Medicines Agency (EMA). more info >> |
|
Wednesday, January 10, 2024 |
|
">
Eisai: "LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in China
|
Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti- soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI" (generic name: lecanemab-irmb) has been approved in China as a treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD dementia. ">more info >> |
|
Friday, December 29, 2023 |
|
Development of Prediction Model for Brain Amyloid-Beta Accumulation Using Wristband Sensor |
Oita University and Eisai Co., Ltd. (Eisai) hereby announce the development of the world's first machine learning model to predict amyloid beta (Abeta) accumulation in the brain using a wristband sensor. more info >> |
|
Tuesday, December 26, 2023 |
|
大分大学とエーザイ、リストバンド型生体センサを用いた脳内アミロイドベータ蓄積予測モデルの開発 |
more info >> |
|
|
|